Clinical Trial Update: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the combination of the STAT inhibitor OPB-111077 with Decitabine and Venetoclax in patients with Acute Myeloid Leukemia who were re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• OPB-111077
• Venetoclax (venetoclax)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED